Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 4606 AL 4620

A 24-Week, Open-Label Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of 13.3 mg/24 h Rivastigmine Patch in Patients With Severe Alzheimer Disease

Farlow MR, Grossberg GT, Sadowsky CH, Meng X, Velting DM.

Alzheimer Dis Assoc Disord. 2015 Apr-Jun;29(2):110-6. doi: 10.1097/WAD.0000000000000073.

Alzheimer's disease and other dementias: advances in 2014

Bateman R.

Lancet Neurol. 2015 Jan;14(1):4-6. doi: 10.1016/S1474-4422(14)70301-1.

SAIDO learning as a cognitive intervention for dementia care: a preliminary study

Kawashima R, Hiller DL, Sereda SL, Antonczak M, Serger K, Gannon D, Ito S, Otake H, Yunomae D, Kobayashi A, Muller C, Murata H, FallCreek S.

J Am Med Dir Assoc. 2015 Jan;16(1):56-62. doi: 10.1016/j.jamda.2014.10.021.

A phase II trial of tideglusib in Alzheimer's disease

Lovestone S, Boada M, Dubois B, Hüll M, Rinne JO, Huppertz HJ, Calero M, Andrés MV, Gómez-Carrillo B, León T, del Ser T; ARGO investigators.

J Alzheimers Dis. 2015;45(1):75-88. doi: 10.3233/JAD-141959.

Drug repositioning approaches for the discovery of new therapeutics for Alzheimer's disease

Kim TW.

Neurotherapeutics. 2015 Jan;12(1):132-42. doi: 10.1007/s13311-014-0325-7.

Dantrolene, a treatment for Alzheimer disease?

Liang L, Wei H.

Alzheimer Dis Assoc Disord. 2015 Jan-Mar;29(1):1-5. doi: 10.1097/WAD.0000000000000076.

[Multifunctional ligands--a new approach in the search for drugs against multi-factorial diseases]

Wichur T, Malawska B.

Postepy Hig Med Dosw (Online). 2015 Jan 2;69:1423-34.

Principles and management of neuropsychiatric symptoms in Alzheimer's dementia

Nowrangi MA, Lyketsos CG, Rosenberg PB.

Alzheimers Res Ther. 2015 Jan 29;7(1):12. doi: 10.1186/s13195-015-0096-3.

Brain metabolism and Alzheimer's disease: the prospect of a metabolite-based therapy

Thomas SC, Alhasawi A, Appanna VP, Auger C, Appanna VD.

J Nutr Health Aging. 2015 Jan;19(1):58-63. doi: 10.1007/s12603-014-0511-7.

A novel prescription for Alzheimer's disease: targeting hypercoagulable states

Maiese K.

Curr Neurovasc Res. 2015;12(1):1-3. doi: 10.2174/1567202612666150107162329.

Receptor for advanced glycation endproduct modulators: a new therapeutic target in Alzheimer's disease

Walker D, Lue LF, Paul G, Patel A, Sabbagh MN.

Expert Opin Investig Drugs. 2015 Mar;24(3):393-9. doi: 10.1517/13543784.2015.1001490. Epub 2015 Jan 14.

Predictive factors of clinical response to cholinesterase inhibitors in mild and moderate Alzheimer's disease and mixed dementia: a one-year naturalistic study

Miranda LF, Gomes KB, Silveira JN, Pianetti GA, Byrro RM, Peles PR, Pereira FH, Santos TR, Assini AG, Ribeiro VV, Tito PA, Matoso RO, Lima TO, Moraes EN, Caramelli P.

J Alzheimers Dis. 2015;45(2):609-20. doi: 10.3233/JAD-142148.

Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease

Dubois B, Chupin M, Hampel H, Lista S, Cavedo E, Croisile B, Louis Tisserand G, Touchon J, Bonafe A, Ousset PJ, Ait Ameur A, Rouaud O, Ricolfi F, Vighetto A, Pasquier F, Delmaire C, Ceccaldi M, Girard N, Dufouil C, Lehericy S, Tonelli I, Duveau F, Colliot O, Garnero L, Sarazin M, Dormont D; “Hippocampus Study Group”; Hippocampus Study Group.

Alzheimers Dement. 2015 Sep;11(9):1041-9. doi: 10.1016/j.jalz.2014.10.003. Epub 2015 Jan 14.

Potential of neural stem cell-based therapies for Alzheimer's disease

Li XY, Bao XJ, Wang RZ.

J Neurosci Res. 2015 Sep;93(9):1313-24. doi: 10.1002/jnr.23555. Epub 2015 Jan 19.

Nutritional supplementation for Alzheimer's disease?

Shea TB, Remington R.

Curr Opin Psychiatry. 2015 Mar;28(2):141-7. doi: 10.1097/YCO.0000000000000138.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias